Methods for regulating endogenous production of checkpoint molecule antagonists
AssigneeWyvern Pharmaceutical Inc.
InventorBradley G. THOMPSON
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for decreasing production and/or functionality of one or more immune checkpoint molecules. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has an infection or infections, or cancer or cancers
Claims52
A method of making an agent/target cell complex, the method comprising a step of administering a therapeutically effective amount of an agent to a subject, wherein the agent/target cell complex increases the subject's endogenous production and/or a functionality of an antagonist of a checkpoint molecule.
A pharmaceutical composition comprising:
- a. an agent that decreases a production and/or a functionality of one or more checkpoint molecules and/or the agent increases a production and/or a functionality of one or more regulatory molecules that decrease a production and/or a functionality of the one or more checkpoint molecules;
- b. a pharmaceutically acceptable carrier;
- and/or
- c. an excipient.
A method of treating an infection, the method comprising a step of administering to a subject a therapeutically effective amount of an agent that decreases a production and/or a functionality of three or more checkpoint molecules.
A method of treating a cancer, the method comprising a step of administering to a subject a therapeutically effective amount of an agent that decreases a production and/or a functionality of three or more checkpoint molecules.
Dependencies are inferred from the claim text.